|
Multimedia
Images, audio, and video related to cancer research
Calendar
Meetings, seminars, and press conferences focused on cancer research
Resources
Information on cancer types, treatment, prevention, and more
 Sponsored by:
The Cancer News Portal is supported by the National Cancer Institute of the National Institutes of Health. Additional information on cancer research, prevention, and treatment is available at www.cancer.gov |
Breaking News
Key: Meeting
Showing releases 1051-1075 out of 1124. << < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>
Public Release: 15-Jun-2012
 Journal of Molecular DiagnosticsResearchers identify need to sample multiple tumor zones in breast cancer Certain short strands of RNA, known as microRNAs (miRNAs), have been linked to the progression and metastasis of breast cancer and may provide information about prognosis. However, studies of miRNA expression profiles often report conflicting findings. While the potential for using miRNAs in breast cancer diagnosis is promising, scientists report in a new study published online today in the Journal of Molecular Diagnostics that differences in the amount and types of miRNA within breast tumors can be misleading. Contact: David Sampson
Public Release: 15-Jun-2012
Cancer DiscoveryMutations in JAK3 gene identified in subtype of lymphoma provide potential drug target A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research. Contact: Jeremy Moore
Public Release: 15-Jun-2012
Journal of Thoracic OncologyQuality of life study shows stereotactic ablative radiotherapy effective treatment; stage I NSCLC Until recently, many elderly patients with stage I non-small cell lung cancer were left untreated because treatment may not improve their quality of life. However, stereotactic ablative radiotherapy (SABR) has become one of the standards of treatment for these patients. The study, presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that the health-related quality of life in these patients does not seem to be negatively affected. Contact: Kristal Griffith
Public Release: 15-Jun-2012
NatureCancer's next magic bullet may be magic shotgun A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects. 
National Institutes of Health, American Cancer Society, Waxman Foundation
Contact: Jason Socrates Bardi
Public Release: 15-Jun-2012
American Journal of Public HealthGraphic warning labels improve smokers' recall of warning and health risks related to smoking In a first of its kind study in the US, researchers at the Perelman School of Medicine at the University of Pennsylvania have shown that the addition of graphic warning labels on cigarette packaging can improve smokers' recall of the warning and health risks associated with smoking. The new findings are published online first in the American Journal of Preventive Medicine. Contact: Jessica Mikulski
Public Release: 15-Jun-2012
Journal of Thoracic OncologyChemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone. Contact: Kristal Griffith
Public Release: 15-Jun-2012
Blood Cancer JournalNanoparticles engineered at Notre Dame promise to improve blood cancer treatment Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow. Contact: Başar Bilgiçer
Public Release: 15-Jun-2012
Journal of Thoracic OncologyHospital volume and surgeon specialty influence patient outcomes Researchers from the Netherlands Cancer Institute wanted to understand if patients undergoing lung cancer resections would benefit from having their procedures performed in a high-volume specialized center. The study, published in the July 2012 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, concluded that hospital volume and surgeon specialty are important factors in patient outcomes. Contact: Kristal Griffith
Public Release: 14-Jun-2012
Current BiologyUnexpected discovery highlights new role for cell death regulator A research team based at Cardiff University's School of Biosciences has already revealed the mechanism by which high alcohol intake can induce pancreatitis and its progression to pancreatic cancer. Now a new study, published in Current Biology, reveals a hitherto unknown interaction between two well known molecules, which has important implications for our understanding of inflammation and cancer in the pancreas as well as other organs.
MRC and Wellcome Trust
Contact: Stephen Rouse
Public Release: 14-Jun-2012
2012 Cancer Survivorship Conference CA: A Cancer Journal for CliniciansNew report estimates nearly 18 million cancer survivors in the US by 2022 The number of Americans with a history of cancer will grow to almost 18 million by 2022, according to a first-ever report by the American Cancer Society and the National Cancer Institute.
American Cancer Society
Contact: David Sampson
Public Release: 14-Jun-2012
DevelopmentQuirky fruit fly gene could point way to new cancer drugs Researchers are taking advantage of a quirk in the evolution of fruit fly genes to help develop new weapons against cancer.
National Institutes of Health
Contact: Jim Ritter
Public Release: 14-Jun-2012
Journal of Biological ChemistryTracking breast cancer cells on the move Breast cancer cells frequently move from their primary site and invade bone, decreasing a patient's chance of survival. This process of metastasis is complex, and factors both within the breast cancer cells and within the new bone environment play a role. In next week's Journal of Biological Chemistry "Paper of the Week," Roger Gomis and colleagues at the Institute for Research in Biomedicine in Spain investigated how breast cancer cells migrate to bone. Contact: Angela Hopp
Public Release: 14-Jun-2012
StructureAtomic-resolution view of a receptor reveals how stomach bacterium avoids acid University of Oregon scientists have discovered how the bacterium Helicobacter pylori navigates through the acidic stomach, opening up new possibilities to inactivate its disease-causing ability without using current strategies that often fail or are discontinued because of side effects.
National Institutes of Health, National Science Foundation
Contact: Jim Barlow
Public Release: 14-Jun-2012
Annals of Internal MedicineVirtual colonoscopy without laxative equals standard in identifying clinically significant polyps Computed tomographic colonography (CTC), also known as virtual colonoscopy, administered without laxatives is as accurate as conventional colonoscopy in detecting clinically significant, potentially cancerous polyps, according to a study performed jointly at the San Francisco VA Medical Center, the University of California, San Francisco and Massachusetts General Hospital.
GE Healthcare, American Cancer Society, Northern California Institute for Research and Education
Contact: Steve Tokar
Public Release: 14-Jun-2012
Cell CycleHow aging normal cells fuel tumor growth and metastasis Researchers at the Kimmel Cancer Center at Jefferson have shown that senescence (aging cells which lose their ability to divide) and autophagy (self-eating or self-cannibalism) in the surrounding normal cells of a tumor are essentially two sides of the same coin, acting as "food" to fuel cancer cell growth and metastasis. Contact: Steve Graff
Public Release: 13-Jun-2012
NatureAdvanced cancers destined to recur after treatment with single drugs that 'target' tumor cells Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.
National Institutes of Health, Virginia and D.K. Ludwig Fund for Cancer Research, National Colorectal Cancer Research Alliance, Swim Across America
Contact: Valerie Mehl
Public Release: 13-Jun-2012
New England Journal of MedicineMoffitt researcher, colleagues find success with new immune approach to fighting some cancers A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1). PD-1 is a key immune "checkpoint" receptor expressed by activated immune cells and is involved in the suppression of immunity.
Bristol-Myers Squibb
Contact: Patty Kim
Public Release: 13-Jun-2012
Journal of Clinical OncologyPsychoeducational intervention changes patient attitudes on clinical trials participation Seeking ways to change cancer patients' perceptions and negative attitudes towards clinical trials participation, researchers at Moffitt Cancer Center conducted a study offering two different kinds of intervention to two groups of adults with cancer who had not previously been asked to participate in clinical trials. They found a multimedia psychoeducational intervention to be more effective in changing patients' perceptions and negative attitudes toward clinical trials than standard educational literature. Contact: Patty Kim
Public Release: 13-Jun-2012
Molecular Cancer ResearchResearchers determine pathway for origin of most common form of brain and spinal cord tumor Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.
Meningioma Mommas Foundation, private donors
Contact: Stephanie Desmon
Public Release: 13-Jun-2012
NatureKey enzyme plays roles as both friend and foe to cancer A molecule thought to limit cell proliferation also helps cancer cells survive during initial tumor formation and when the wayward cells spread to other organs in the body, researchers at the University of Illinois at Chicago College of Medicine have found.
National Institutes of Health, Chicago Biomedical Consortium, Searle Funds at the Chicago Community Trust, Diabetes Research and Training Center at the University of Chicago
Contact: Jeanne Galatzer-Levy
Public Release: 12-Jun-2012
Physics Review LettersTiny 'speed bump' device could sort cancer cells Engineers have found an easy way to sort microscopic particles and bits of biological matter, including circulating tumor cells.
National Institutes of Health, National Science Foundation
Contact: Mary Spiro
Public Release: 12-Jun-2012
Journal of Clinical OncologyMarker distinguishes more-aggressive from less-aggressive forms of chronic leukemia Researchers have identified a prognostic marker in chronic lymphocytic leukemia (CLL) that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years. Currently, doctors must simply observe newly diagnosed patients to determine which type of CLL they have. This can delay the start of treatment in patients with aggressive disease, or it can lead to treating patients who don't yet require it.
NIH/National Cancer Institute, Herman Research Society, Leukemia and Lymphoma Society, Harry Mangurian Foundation, D. Warren Brown Foundation
Contact: Darrell E. Ward
Public Release: 12-Jun-2012
New England Journal of MedicineNew England Journal of Medicine hails new skin cancer drug as 'greatest advance yet' Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma by the New England Journal of Medicine. Vismodegib (marketed under the name Erivedge) was administered for the first time at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute.
Genentech
Contact: Steve Yozwiak
Public Release: 12-Jun-2012
2012 American Society of Clinical Oncology Annual MeetingUSC Norris clinicians discuss cancer research results USC Norris Comprehensive Cancer Center physician-researchers collaborated on more than 70 research projects presented at the 2012 annual meeting of the American Society of Clinical Oncology this month.
NIH/National Cancer Institute, National Institutes of Health, and others
Contact: Alison Trinidad
Public Release: 12-Jun-2012
Proceedings of the National Academy of SciencesProtein residues kiss, don't tell Jose Onuchic and colleagues at the Center for Theoretical Biological Physics have developed a tool, known as direct coupling analysis-fold, that enhances existing methods. Details of their research appear today in the online version of the Proceedings of the National Academy of Sciences.
National Science Foundation/Center for Theoretical Biological Physics
Contact: David Ruth
Showing releases 1051-1075 out of 1124. << < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>
|
Search News Releases
|
|||||||||||||||||||||||||
 |
||||
|
|
 |
|